Akciğer tüberkülozunda serum matriks metalloproteinaz-9 düzeyleri

Amaç: Akif akciğer tüberkülozlu (TB| hastalarsın serum matrix metaIlloprotdnase-9 ((MMP-9J düzeylerinin hastalığın tanasına Jcattara saptamak için bu çalışmayı planladık. Gereç ve Yöntem: Çalışmaya Ağustos 2OO5HMarî 2006 tarihleri arasında Miniğimizde hospitalize edilen yirmidört akciğer TBIu hasla alındı. Kontrol gruplan olarak, yirmi dört kişiden oluşan bir toplum kökenli pnöımonii fTKP) hasta grubu ve yirmi dört kişilik başka bir sağlıklı grup çalışmaya dahil edildi. Tüm hastaların serum örneklerinde MMP-9 EÜSA yöntemiyle ölçüldü. Bulgular: Serum JMMP-9 düzeyleri yönünden 3 grup karşılaşbnldığı zaman aralannda istatlkseS olarak anlamlı fark olduğunu saptadık (p=0.001}. Akciğer IB'lu hastalann serum MyP-9 düzeyleri sağlıklı kontrol grubundan istaîiksel olarak anlamlı derecede düşük bulundu (p=0.009j. Toplum kökenli pnömoni hastalan île pulmoner TBllu hastalar arasında fark tespit edilmedi. Sonuç: Bizim bulgularımız akdğer tüberkülbzlu hastalarının serum yyP-9 düzeylerinin sağlıklı kişilerden düşük olabileceğini göstermektedir. Bu faric îstaîâksel olarak anlamlı olduğu için yine bizim bulgularımız serum MMP-9 düzeylerinîn akciğer tüberkülozunun tanıısama bir miktar ek katta sağlayabileceğini düşündürmektedir. Diğer yandan MMP-9'un akciğer tüberkülozunun ayına tanısında ön saralarda yer alan toplum kökenli pnönonlerle ayrımında îaossal öneminin olmadığa görülmektedir.

Serum matrix metalloproteinase-9 levels in pulmonary tuberculosis

Aim: We planned this study to determine the diagnostic yield of serum matrix meta31oproteinase-9 (MMP-9) levels in the pulmonary tuberculosis (IB) patients. . Methods: Twenty four pulmonary TB patients, who were hospîalized in our clinic between .August 2005 and March 2006. /te control groups were enrolled into this study. Group consisting of twenty lour community acquiied pneumonia (CAP) patients and another group consisting of twenty lour healthy people were also included into the study. My P-9 measured by EUSA method in the serums of all patients. Results: When we compared 3 groups in terms of serum yyiP-9 levels, we noticed that there was a statistically significant difference between the three groups fp=0.001). In pulmonary TB patients, serum MMP-9 level were statistically lower than that in healthy control group (p=0.009). There was no difference between CAP and pulmonary TB patients. Conclusion: Our results suggest that in active pulmonary TB patients serum MMP-9 levels might be lower than that in the healthy people. Since the difference was statistically significant our results also suggest that serum MMP-9 levels may have some contribution to the diagnosis of pulmonary TB. On the other hand, it seems f^MP-9 have no diagnostic value in distinguishing CAP, leading cause ' of the differential diagnosis, from pulmonary TB.

Kaynakça

1. Friedland İS, Shaw TC Price HM, DayerJM,. Differential; regulation of MIMIP1/9 and TIMP-l secrectiıon in human ımonocyölc cells in response to Mycobacteifiunn tuberculosis. Matrix Biology 2QOZ; 21: 103- 10.

2.Quiding Jarbrink; M, Smith DA, Bancroft GJ. Production of matrix metalfaproteinases in response to mycobacterial; infection. Infect Immun ZO01; 69: 5661 - 70.

3.Price IMM, Gilman RH, Udin X Recavarren S,. Friedland JS. Unopposed matnk metaltoprotdnase 9 expression in human tuberculous granuionrra and the role of TfNF dependent monacyte networks.. J Immunol 2003; 171:55.79-86.

4. Elkington PTG, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Bxp Immunol: Z005; 14Z: 1Z- 20.

5. Elkington PTG, Friedland JS. Matrix metailoproteinases in destructive pulmonary pathology. Occasional: Review. Thorax Z006; 61: 259-66.

6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalioproteinases structure, function, and biochemistry, review. Circulation Research Z003; 92: 8Z7- 39.

7. Hrabec Er Strefc M, Ziefcia Mv Kwiatkowska S, Hrabec Z. Qrculation level of matrix metal:l:oproteinase 9 correlated with disease severityin tuberculosis patients. Int J Tuberc Lung Dis 2002; 6: 713- 9.

8. Kleiner DE, Stetlerstevenson WG. Quantitative zymography: Detection of picogram quantities of gelatinases. Analytic Biochem 1994; 218: 325- 9.

9. Fishman PA. Pulmonary Diseases and Disorders, Third Edition, USA. 2002: 348.

10. Chang JC, Wysocki A, Tchou Wong KM, Moskowitz N, Zhang Y, Rom WN. Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996; 51: 306- 1 1.

11. Rivera Marrero CA Schuyler W, Roser S, Roman J. Induction of MMP 9 mediated gelatinolytic activity in human monocytic cells by cell wall components of Mycobacterium tuberculosis. Microb Pathog 2000; 29: 231-44.

12. Hoheisel G, Sack U, Hui DSC, Huse K, Chan KS, Chan KK, et al. Occurence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis. Tuberculosis 2001; 81: 203- 9.

13. Hoheisel G, Sack D, Hui DS, Lai F. Immunohistochemical localization of matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in tuberculous pleuritis. Pneumologic 2004; 58: 305- 8.

14. Park KJ, Hwang SC, Sheen SS, Oh YJ, Han JH, Lee KB. Expression of matrix metalloproteinase 9 in pleural effusions of tuberculosis and lung cancer. Respiration, 2005; 72: 166- 75.

15. Iglesias D, Alegre J, Aleman C, Ruiz E, Sorino T, Armandans LI. Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions. Eur Respir J 2005; 25: 104- 9.

16. Bilgiç H, Demirci N. Tüberküloz. Birinci Baskı. Ankara: GATA Basımevi, 2003: 68.

17. Kim HJ, Lee HJ, Kwon SY, Yoon HI, Chung HS, et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest 2006; 129: 1253- 58.

18. Mihmanlı A Özşeker F, Baran A Küçüker F, Atik S, Akkaya E. Evaluation of 105 cases with tuberculous pleurisy. 2004; 52: 137- 44.

19. Conde MB, Loivos AC, Rezende VM, Soares SL, Mello FC, Reingold AL, et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. 2003; 167: 723- 5.

20. Lee KY, Kim EH, Yang WS, Ryu H, Cho HN, Lee Bl, Heo JH. Persistent increase of matrix metalloproteinases in cerebrospinai fluid of tuberculous meningitis. J Neurol Sciences 2004; 220: 73- 8.

21. Matsuura E, Umehara F, Hashiguchi T, Fujimoto N, Okada Y. Marked increase of matrix metalloproteinase 9 in cerebrospinai fluid of patients with fungal or tuberculous meningoencephalitis. J Neurol Sciences 2000; 173: 45-52.

22. Hartog CM, Wermelt JA, Sommerfeld CO, et al. Pulmonary matrix metalloproteinase excess in hospital acquired pneumonia. Am J Respir Crit Care Med 2003; 167: 593- 8.

23. Yang SF, Chu SC, Chaing IC, Kuo WF. Excessive matrix metalloproteinase- 9 in the plasma of community acquired pneumonia. Clinica Chimica Acta 2005; 352: 209- 15.

Kaynak Göster